Abstract: Novel phosphine and phosphine oxide ligands are prepared using polymeric supports. These compounds can be easily cleaved from the support, and along with the corresponding supported compounds, used as ligands in the preparation of novel, metal-complexed catalysts.

Abstract: The present invention relates to a process comprising using ionic liquids for the polycondensation of 1,3-propanediol reactants to produce polytrimethylene ether glycol and copolymers thereof.

Abstract: The present invention relates to a process for preparing sulfur-containing compounds of the general formula I in which Q, R1 and R2 are each independently defined as follows: Q: —S— or —S—S—, R1: hydrogen or saturated or unsaturated, linear or branched C1-C30-alkyl radical, R2: hydrogen or saturated or unsaturated, linear or branched C1-C30-alkyl radical, where R1 and R2 are not simultaneously hydrogen, by reacting a mixed gas stream comprising hydrogen sulfide, with or without oxygen, with linear or branched C1-C30-olefins, which comprises carrying out the reaction in the presence of water and carbon dioxide at a pressure of from 2 to 325 bar.

Abstract: Compounds according to formula (I) wherein Z is S, SO, or SO2, may be prepared by a process that includes charging to a reactor hydrogen sulfide and an alkyl glycidyl ether according to formula (III), in the presence of a base.

Abstract: Methods of forming intermediates from PHAs are disclosed.

Abstract: The invention relates to a process for the preparation of cycloorganylphosphanes of formula 1 (R1P)n by reaction of dihalo(organyl)phosphanes of formula R1PHal2 with: a) activated zinc in an organic solvent, or with: b) an alkali metal or alkaline earth metal in a non-polar organic solvent in the presence of an activator, wherein R1 is C1–C12alkyl; C3–C12 cycloalkyl, aryl or heteroaryl, Hal is F, Cl, Br or I, and n is a number from 3 to 20. The invention relates also to novel di(alkali metal/alkaline earth metal) oligophosphanediides and to the use thereof in the preparation of organophosphorus compounds.

Abstract: The invention provides a process for preparing R-(+)-2-(4-hydroxyphenoxy)-2-methyl-butyric acid methyl ester of the formula (I): Various embodiments and variants are provided. The invention also provides a process for preparing S-(?)-2-(4-hydroxyphenoxy)-2-methyl-butyric acid methyl ester of the formula (II) Various embodiments and variants are provided.

Abstract: The present invention is generally directed to electroluminescent Ir(III) compounds with phosphinoalkoxides and phenylpyridines or phenylpyrimidines, and devices that are made with the Ir(III) compounds.

Abstract: The continuous process for manufacturing bisphenol A according to the invention, by reacting phenol and acetone in the presence of a strong acid catalyst and a co-catalyst, is carried out using as co-catalyst a dithio ether of general formula: in which the symbols R and R? each represent a hydrogen atom, an alkyl radical or a phenyl radical, and the symbol R? represents an optionally substituted alkyl radical.

Abstract: Novel compounds and compositions including those compounds, as well as methods of using and making the compounds are herein described. The compounds are useful in therapeutic applications, including modulation of disease or disease symptoms in a subject (e.g., mammal, human, dog, cat, horse). The compounds are useful as modulators of the mu opioid receptor (MOR) through their binding affinity with that receptor.

Abstract: Arylcycloalkyl derivatives having branched side chains, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl derivatives having branched side chains and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

Abstract: A novel class of dicarboxylic acid derivatives, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: The present invention relates to a method of producing a compound represented by the formula [I] or a salt thereof, which comprises reacting a compound represented by the formula [II] or a salt thereof with a compound represented by the formula [III] or a salt thereof, in the presence of a base, in alcohol, and provides a production method of an O-substituted tyrosine compound, which is superior in productivity, versatility and safety, and economically and industrially useful: wherein each symbol is as defined in the specification.

Abstract: A process for selectively making 2-thiols from alpha olefins is described. The process includes contacting a linear or branched alpha olefin having with H2S in the presence of a catalyst and recovering the 2-thiol from a product mixture. The catalyst includes a support and at least one metal selected from Group IIIA-VIIIA and the branched olefin is branched at the 3-position or higher with respect to the olefin double bond. Compositions wherein the 2-thiols are substantially free of 1-thiol and 3-thiol isomers are also described.

Abstract: A compound of the formula (1): wherein PCA represents a polycycloaliphatic hydrocarbon group, ALK represents a divalent aliphatic hydrocarbon group, m is 1 or 2, n is 0 or 1, and R1 and R2 represent independently each other an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryl group or an aryloxy group.

Abstract: Provided is a method for the synthesis of 1,4-dicyclopropyl-1,3-butadiyne from CPA. Such butadiyne is prepared by oxidative coupling of cyclopropyl acetylene (CPA) using catalytic amounts each of copper (I)chloride and tetrametylethylenediamine (TMEDA) in isopropanol under aerobic conditions. The resulting butadiyne can serve as a fuel or a fuel additive for combustion in engines propelling motor vehicles, marine vessels, aircraft, rockets and other vehicles.

Abstract: The invention provides the use of compounds of the formula (1) where R1, R2 are each independently C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, R3 is C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, —CHR5—COO? or —O?, R4 is M, hydrogen or an organic radical which optionally contains heteroatoms and has from 1 to 100 carbon atoms, B is an optionally substituted C1- to C30-alkylene group, D is an organic radical which optionally contains heteroatoms and has from 1 to 600 carbon atoms, X, Y are each independently O or NR6, R5, R6 are each independently hydrogen, C1- to C22-alkyl, C2- to C22-alkenyl, C6- to C30-aryl or C7- to C30-alkylaryl, and M is a cation as gas hydrate inhibitors.

Abstract: The present invention provides a method for producing optically active flurbiprofen. The method of the present invention includes mixing racemic flurbiprofen and (S)- or (R)-3-methyl-2-phenylbutylamine in an organic solvent to produce a diastereomeric salt; and treating the diastereomeric salt with an acid in a second solvent. In the method of the present invention, flurbiprofen having a desired absolute configuration can be obtained very efficiently without repeating the procedure for optical resolution a plurality of times.

Abstract: The present invention relates to a method for the chemical separation of the enantiomers of 1,1?-spirobiindane-6,6?-diol derivatives comprising providing a racemic chiral 1,1?-spirobiindane-6,6?-diol derivative, reacting a nonracemic chiral component with the racemic chiral 1,1?-spirobiindane-6,6?-diol derivative to afford a mixture of diastereomeric diesters, separating the mixture of diastereomeric diesters to provide a substantially pure individual diastereomeric diester, and chemically removing the ester groups from the substantially pure individual diastereomeric diester to provide a nonracemic chiral 1,1?-spirobiindane-6,6?-diol derivative.

Abstract: This invention provides a compound of the formula (I): wherein R1 represents a (C1–C6)alkyl group; R2 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C1–C6)alkyl group or a (C1–C6)alkoxy group; R3, R4, R5 and R6 each independently represents a hydrogen atom, a (C1–C6)alkyl, or a halogen atom; R7 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C1–C6)alkyl group optionally substituted with a piperidino group, a (C1–C6)alkoxy group optionally substituted with a 3–7 membered cycloalkyl ring, a hydroxy(C1–C6)alkoxy group, a (C1–C6)alkoxy-(C1–C6)alkyl group, a (C1–C6)alkoxy-(C1–C6)alkoxy group, a halo (C1–C6)alkyl group, a (C1–C6)alkylthio group, a (C1–C6)alkylsulfinyl group or a (C1–C6)alkylsulfonyl group; R8 represents a (C1–C6)alkyl group, a halo(C1–C6)alkyl group, a (C1–C6)alkoxy group, a hydroxy(C1–C6)alkoxy group, a (C1–C6)alkoxy-(C1–C6)alkyl group or a (C1–C6)alkoxy-(C1–C6)alkoxy group; or R7 and R8, when adjacent to each other, taken together with the carbon atoms to whic